Table 1.
Baseline characteristics
| Variable | Analytical Cohort (n = 239) | Randomized Patients (n = 208) | Patients Who Did Not Complete Baseline (n = 31) |
|---|---|---|---|
| Age (years) | 50.1 ± 13.6 | 50.1 ± 13.4 | 49.8 ± 15.0 |
| Female | 97 (41%) | 84 (40%) | 13 (42%) |
| Black race | 100 (42%) | 91 (44%) | 9 (29%) |
| ESRD vintage (years) | 3.16 (1.33; 6.48) | 3.63 (1.60; 6.93) | 1.68 (1.07; 2.54) |
| Diabetesa | 97 (42%) | 87 (42%) | 10 (40%) |
| Congestive heart failurea | 48 (21%) | 41 (20%) | 7 (28%) |
| COPDa | 13 (6%) | 10 (5%) | 3 (12%) |
| Past myocardial infarctiona | 30 (13%) | 25 (12%) | 5 (20%) |
| Peripheral vascular diseasea | 26 (11%) | 22 (11%) | 4 (16%) |
| Charlson comorbidity indexa | |||
| 0 | 93 (40%) | 83 (40%) | 10 (40%) |
| 1 | 40 (17%) | 37 (18%) | 3 (12%) |
| 2 | 40 (17%) | 38 (18%) | 2 (8%) |
| 3–4 | 42 (18%) | 36 (17%) | 6 (24%) |
| 5–6 | 14 (6%) | 12 (6%) | 2 (8%) |
| 7–12 | 4 (2%) | 2 (1%) | 2 (8%) |
| Beta blockera | 139 (60%) | 126 (61%) | 13 (50%) |
| Calcium channel blockera | 120 (51%) | 110 (53%) | 10 (38%) |
| Aspirina | 89 (38%) | 78 (38%) | 11 (42%) |
| Statins and/or other lipid lowering medicationsa | 83 (35%) | 76 (37%) | 7 (27%) |
Descriptive data are presented as mean ± SD or median and quartiles for normal and skewed population data, respectively. COPD, chronic obstructive pulmonary disease.
a
Missing data in five to six patients among the analytical cohort.